The electrocardiographic features, imaging manifestations and prognostic influencing factors of hepatitis B-related cirrhotic cardiomyopathy

Abstract

Abstract: Objective To analyze the electrocardiographic characteristics, imaging manifestations and prognostic influencing factors of hepatitis B-related cirrhotic cardiomyopathy, and to provide a basis for improving the prognosis of patients. Methods Sixty-five patients with hepatitis B-related liver cirrhosis admitted to First Affiliated Hospital of Air Force Medical University from April 2021 to April 2023 were enrolled in this study. According to whether they developed hepatitis B-related cirrhotic cardiomyopathy, they were divided into an occurrence group (n=40) and a control group (n=25). The occurrence group was further classified into a good prognosis group (25 cases, 1 case of lossing follow-up) and a poor prognosis group (13 cases , 1 case of lossing follow-up). Blood creatinine (Scr) and hemoglobin (Hb) were detected using a fully automated biochemical immunoassay analyzer; prothrombin time (PT) was detected using a fully automated coagulation analyzer; imaging features were detected using a color Doppler ultrasound diagnostic machine; and electrocardiography was performed using an electrocardiograph. The imaging and electrocardiogram examination indexes in the occurrence group and control group were compared. The influencing factors for the prognosis of hepatitis B-related cirrhotic cardiomyopathy were analyzed using multifactorial logistics. Results The left atrial inner diameter (LAD), diastolic ventricular septal thickness (IVSD), Q-T interval prolongation, ST-T changes, and the percentage of low voltage in the occurrence group were (39.2±4.6) mm, (12.8±1.5) mm, 75.0%, 70.0%, and 30.0% in the occurrence group, respectively, which were higher than those of [(34.2±2.8) mm, (10.5±1.1) mm, 36.0%, 28.0%, and 8.0%] in the control group. The E/A ratio was (0.7±0.1) in the occurrence group, which was lower than that of (1.4±0.3) in the control group (P<0.05). The percentages of Child-Pugh classification C, Q-T interval prolongation, ST-T changes, and low voltage in the adverse group were 69.2%, 61.5%, 53.9%, and 61.5%, respectively, which were significantly higher than those of 20.0%, 16.0%, 8.0%, and 12.0% in the survival group (P<0.05). The results of multifactorial logistic regression analysis showed that Child-Pugh classification, Q-T interval prolongation, ST-T changes, and low voltage were factors affecting the prognosis of patients with hepatitis B-related cirrhotic cardiomyopathy (OR=3.490, 3.842, 3.466, 3.684, respectively, P<0.05). Conclusion Child-Pugh classification, Q-T interval prolongation, ST-T changes, and low voltage are factors affecting the prognosis of patients with hepatitis B-related cirrhotic cardiomyopathy.

Key words: Hepatitis B cirrhosis, Cardiomyopathy, Electrocardiographic features, Prognosis, Influencing factors

ZHU Ying, NIU Jing, XU Yuan-ping, TIE Jun. The electrocardiographic features, imaging manifestations and prognostic influencing factors of hepatitis B-related cirrhotic cardiomyopathy[J]. Chinese Hepatolgy, 2026, 31(3): 351-355.

References

[1] 陈颖, 方亮, 刘正爱, 等. 乙肝肝硬化患者血清HBV-DNA载量与HSP70、CEA及AFP水平的相关性[J]. 中华医院感染学杂志, 2020, 30(23): 3607-3611.
[2] Hsu Y C, Huang D Q, Nguyen M H. Global burden of hepatitis B virus: current status, missed opportunities and a call for action[J]. Nat Rev Gastroenterol Hepatol, 2023, 20(8): 524-537.
[3] Wang Q, Zhao H, Deng Y, et al. Validation of Baveno Ⅶ criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis[J]. J Hepatol, 2022, 77(6): 1564-1572.
[4] Loureiro D, Tout I, Narguet S, et al. Mitochondrial stress in advanced fibrosis and cirrhosis associated with chronic hepatitis B, chronic hepatitis C, or nonalcoholic steatohepatitis[J]. Hepatology, 2023, 77(4): 1348-1365.
[5] 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 中华肝脏病杂志, 2019, 27(12): 938-961.
[6] European Association for the Study of the Liver.EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69(2): 406-460.
[7] 刘丽, 江颖仪, 刘景. 不同Child-Pugh分级慢性乙型肝炎肝硬化患者糖代谢、胰岛素分泌情况及其与炎症反应的相关性分析[J]. 临床肝胆病杂志, 2020, 36(2): 324-328.
[8] Moon A M, Singal A G, Tapper E B. Contemporary epidemiology of chronic liver disease and cirrhosis[J]. Clin Gastroenterol Hepatol, 2020, 18(12): 2650-2666.
[9] Ghany M G, Saraswat V A. Patients with compensated hepatitis B virus-related cirrhosis and low-level viremia: treat or not to treat?[J]. Am J Gastroenterol, 2023, 118(6): 970-971.
[10] GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet Gastroenterol Hepatol, 2020, 5(3): 245-266.
[11] Mihalcea L, Sebastian I, Simion-Cotorogea M, et al. Reverse takotsubo cardiomyopathy after orthotopic liver transplantation.A Case Report[J]. J Crit Care Med (Targu Mures), 2022, 8(2): 117-122.
[12] Smith E D, Lakdawala N K, Papoutsidakis N, et al. Desmoplakin cardiomyopathy, a fibrotic and inflammatory form of cardiomyopathy distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathy[J]. Circulation, 2020, 141(23): 1872-1884.
[13] Izzy M, VanWagner L B, Lin G, et al. Redefining cirrhotic cardiomyopathy for the modern era[J]. Hepatology. 2020, 71(1): 334-345.
[14] Toma L, Stanciu A M, Zgura A, et al. Electrocardiographic changes in liver cirrhosis-clues for cirrhotic cardiomyopathy[J]. Medicina (Kaunas), 2020, 56(2): 68.
[15] Wang C, Gao H, Liu W, et al. Alcoholic cardiomyopathy in patients with alcoholic liver cirrhosis: a study across 10 years[J]. Eur J Gastroenterol Hepatol, 2023, 35(5): 600-603.
[16] de Souza S L B, Mota G A F, Gregolin C S, et al. Exercise training attenuates cirrhotic cardiomyopathy[J]. J Cardiovasc Transl Res, 2021, 14(4): 674-684.
[17] Liu J, Zhao S, Yu S, et al. Patterns of replacement fibrosis in hypertrophic cardiomyopathy[J]. Radiology. 2022, 302(2): 298-306.
[18] Møller S, Wiese S, Barløse M, et al. How non-alcoholic fatty liver disease and cirrhosis affect the heart[J]. Hepatol Int, 2023, 17(6): 1333-1349.
[19] Izzy M, Lin G, Watt K D. Non-selective beta blockers and mortality in decompensated cirrhosis: is cirrhotic cardiomyopathy the missing link?[J]. J Hepatol. 2021, 75(4): 992-993.
[20] Cojan-Minzat B O, Zlibut A, Agoston-Coldea L. Non-ischemic dilated cardiomyopathy and cardiac fibrosis[J]. Heart Fail Rev, 2021, 26(5): 1081-1101.